Sciele Pharma and Plethora Solutions Announce Positive Phase III
PR-Inside.com (Pressemitteilung), Austria - Nov 9, 2008
European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation ('PE') has met its three co-primary endpoints